RNXT Stock Summary and Trading Ideas (Renovorx | NASDAQ:RNXT)

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical needs with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed for targeted therapeutic delivery across the arterial wall near the tumor site (known as intra-arterial, or IA delivery) to bathe the target tumor, while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

Renovorx trades on the NASDAQ stock market under the symbol RNXT.

As of September 10, 2026, RNXT stock price declined to $1.77 with 1,590,511 million shares trading.

RNXT has a beta of 1.29, meaning it tends to be more sensitive to market movements. RNXT has a correlation of 0.03 to the broad based SPY ETF.

RNXT has a market cap of $79.83 million. This is considered a Micro Cap stock.

Last quarter Renovorx reported $909,000 in Revenue and -$.05 earnings per share. This beat revenue expectation by $200,000 and exceeded earnings estimates by $.03.

In the last 3 years, RNXT traded as high as $2.59 and as low as $.53.

The top ETF exchange traded funds that RNXT belongs to (by Net Assets): VTI, VXF.

RNXT has outperformed the market in the last year with a price return of +52.6% while the SPY ETF gained +17.7%. RNXT has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +105.8% and +18.8%, respectively, while the SPY returned +3.1% and -1.1%, respectively.

RNXT support price is $1.82 and resistance is $2.17 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RNXT shares will trade within this expected range on the day.